UNSPSC 51142022: Dibupyrone

This classification denotes an analgesic and antipyretic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T99M8X4T54. European Medicines Agency schedules Dibupyrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07079MIG. Dibupyrone generally arises in the molecular formula C16H22N3O4S.NA. The term DIBUPYRONE is an International Non-Proprietary Name or INN. DIBUPYRONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule dibupyrone under HS 29331190 and SITC 51571. As of Q4 2014, DIBUPYRONE remains the US FDA Preferred Term for this commodity. Dibupyrone bears US NLM identifiers UMLS ID C2699626 and NCI Concept Code C77319. SMILES: S(=O)(=O)(O)CN(CC(C)C)C1C(N(N(C1=O)C1CCCCC1)C)C.[NA].

UNSPSC 51142022 Dibupyrone is a Commodity code that state and local governments use to tag pharmaceutical procurement, though recent solicitations under this code show activity in naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs rather than dibupyrone specifically. State and local health agencies, cooperative purchasing alliances, and county health departments are the primary issuing bodies. The work encompasses purchase of finished pharmaceutical products (naloxone, generic medications, over-the-counter items), negotiation of direct-to-manufacturer relationships to bypass traditional pharmacy benefit managers and wholesalers, and supply chain logistics including storage, quarterly delivery schedules, and compliance with FDA manufacturing practices and federal supply chain security regulations. Vendors must typically maintain relationships with authorized wholesalers, meet cGMP and Drug Supply Chain Security Act certifications, carry substantial commercial general liability and professional liability insurance, and comply with drug-free workplace and E-Verify requirements.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, potentially FEMA-funded. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, with formal RFP to follow. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with award effective July 1, 2026 and a two-year term. MMCAP's evaluation weights price competitiveness at 75 percent and requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) with chargeback systems in place.